Logo image of IGC

IGC PHARMA INC (IGC) Stock Fundamental Analysis

NYSEARCA:IGC - NYSE Arca - US45408X3089 - Common Stock - Currency: USD

0.35  +0.02 (+6.06%)

Fundamental Rating

1

Overall IGC gets a fundamental rating of 1 out of 10. We evaluated IGC against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IGC have multiple concerns. IGC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IGC had negative earnings in the past year.
IGC had a negative operating cash flow in the past year.
IGC had negative earnings in each of the past 5 years.
In the past 5 years IGC always reported negative operating cash flow.
IGC Yearly Net Income VS EBIT VS OCF VS FCFIGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

IGC has a Return On Assets of -81.41%. This is in the lower half of the industry: IGC underperforms 73.06% of its industry peers.
The Return On Equity of IGC (-112.50%) is worse than 61.14% of its industry peers.
Industry RankSector Rank
ROA -81.41%
ROE -112.5%
ROIC N/A
ROA(3y)-93.23%
ROA(5y)-72.05%
ROE(3y)-122.42%
ROE(5y)-91.4%
ROIC(3y)N/A
ROIC(5y)N/A
IGC Yearly ROA, ROE, ROICIGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

With a decent Gross Margin value of 48.70%, IGC is doing good in the industry, outperforming 62.18% of the companies in the same industry.
In the last couple of years the Gross Margin of IGC has grown nicely.
IGC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.84%
GM growth 5Y75.22%
IGC Yearly Profit, Operating, Gross MarginsIGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

IGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IGC has been increased compared to 1 year ago.
Compared to 5 years ago, IGC has more shares outstanding
The debt/assets ratio for IGC is higher compared to a year ago.
IGC Yearly Shares OutstandingIGC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IGC Yearly Total Debt VS Total AssetsIGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -14.86, we must say that IGC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IGC (-14.86) is worse than 77.20% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that IGC is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.02, IGC perfoms like the industry average, outperforming 55.96% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -14.86
ROIC/WACCN/A
WACC9.97%
IGC Yearly LT Debt VS Equity VS FCFIGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M

2.3 Liquidity

IGC has a Current Ratio of 1.28. This is a normal value and indicates that IGC is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.28, IGC is not doing good in the industry: 76.68% of the companies in the same industry are doing better.
A Quick Ratio of 0.68 indicates that IGC may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.68, IGC is doing worse than 87.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 0.68
IGC Yearly Current Assets VS Current LiabilitesIGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.82% over the past year.
IGC shows a decrease in Revenue. In the last year, the revenue decreased by -5.78%.
The Revenue for IGC have been decreasing by -20.77% on average. This is quite bad
EPS 1Y (TTM)57.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.59%
Revenue 1Y (TTM)-5.78%
Revenue growth 3Y47.02%
Revenue growth 5Y-20.77%
Sales Q2Q%11.86%

3.2 Future

Based on estimates for the next years, IGC will show a decrease in Earnings Per Share. The EPS will decrease by -1.65% on average per year.
IGC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.74% yearly.
EPS Next Y-5.89%
EPS Next 2Y-1.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.45%
Revenue Next 2Y9.74%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IGC Yearly Revenue VS EstimatesIGC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
IGC Yearly EPS VS EstimatesIGC Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.05 -0.1 -0.15 -0.2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IGC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IGC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IGC Price Earnings VS Forward Price EarningsIGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IGC Per share dataIGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.65%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IGC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IGC PHARMA INC

NYSEARCA:IGC (7/17/2025, 2:26:35 PM)

0.35

+0.02 (+6.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)06-27 2025-06-27
Earnings (Next)08-06 2025-08-06
Inst Owners20.94%
Inst Owner ChangeN/A
Ins Owners3.33%
Ins Owner Change0%
Market Cap29.36M
Analysts80
Price Target3.95 (1028.57%)
Short Float %0.67%
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.05%
Min Revenue beat(2)0.97%
Max Revenue beat(2)7.13%
Revenue beat(4)3
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-40.88%
Max Revenue beat(4)38.04%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.1
P/FCF N/A
P/OCF N/A
P/B 4.64
P/tB 6.56
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.02
BVpS0.08
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.41%
ROE -112.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.7%
FCFM N/A
ROA(3y)-93.23%
ROA(5y)-72.05%
ROE(3y)-122.42%
ROE(5y)-91.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.84%
GM growth 5Y75.22%
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.99%
Cap/Sales 37.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 0.68
Altman-Z -14.86
F-Score3
WACC9.97%
ROIC/WACCN/A
Cap/Depr(3y)84.26%
Cap/Depr(5y)139.57%
Cap/Sales(3y)48.11%
Cap/Sales(5y)101.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.59%
EPS Next Y-5.89%
EPS Next 2Y-1.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.78%
Revenue growth 3Y47.02%
Revenue growth 5Y-20.77%
Sales Q2Q%11.86%
Revenue Next Year16.45%
Revenue Next 2Y9.74%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.77%
OCF growth 3YN/A
OCF growth 5YN/A